Earnings Report for November 11, 2025: ALC, OKLO, DOX, CAE, ORLA, SMWB, HYLN, LPTH, STXS, PAL, EPM, QUIK Released After Market Hours
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy STXS?
Source: NASDAQ.COM
Earnings Reports Overview: Several companies, including Alcon Inc., Oklo Inc., and Amdocs Limited, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Alcon Inc. Performance: Alcon Inc. is expected to report earnings per share (EPS) of $0.77, a 4.94% decrease from the previous year, and has a Price to Earnings (P/E) ratio of 24.07, indicating potential growth compared to industry competitors.
Oklo Inc. and Other Companies: Oklo Inc. anticipates a significant EPS drop to -$0.13, while other companies like CAE Inc. and Similarweb Ltd. also project declines in EPS compared to the same quarter last year.
Mixed Results Across Sectors: Companies such as Proficient Auto Logistics and Evolution Petroleum Corporation are expected to show minimal changes or declines in EPS, reflecting a diverse range of financial health across different sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.070
Low
4.00
Averages
4.20
High
5.00
Current: 2.070
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stereotaxis Reports 36% Revenue Growth in Q4
- Significant Revenue Growth: Stereotaxis Inc (STXS) reported fourth-quarter revenue of $8.6 million, a 36% increase from $6.3 million in the prior year, reflecting strong performance in system and catheter sales, which enhances the company's competitive position in the medical device market.
- Product Portfolio Expansion: The company plans to launch MAGiC with Pulse Field Ablation in Europe by year-end, aiming to boost revenue potential through new product marketing, although the commercial contribution from new products remained modest in 2025.
- Operational Cost Challenges: Operating expenses for Q4 reached $10 million, including $3 million in non-cash charges, and while adjusted operating expenses were $7 million, high operational costs continue to pressure financial results, impacting the company's profitability.
- Cash Flow Position: As of the end of 2025, Stereotaxis had cash and cash equivalents of $13.4 million, facing a negative free cash flow of $13.8 million; however, the company's debt-free status provides a safeguard for future growth.
See More
Stereotaxis Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Q4 2025 revenue reached $8.6 million, a 36% increase year-over-year, reflecting substantial progress in catheter sales, with annual revenue projected to exceed $40 million in 2026, indicating strong market demand and growth potential.
- Technological Advancements and Regulatory Milestones: The company achieved regulatory approvals for the GenesisX robot and MAGiC catheters in the U.S. and Europe, underscoring its leadership in minimally invasive surgery technology, which is expected to drive future sales and market share growth.
- Commercial Model Transformation: Stereotaxis is shifting from large capital sales to a model based on sales, leases, and placements funded by disposable commitments, increasing revenue per procedure from $1,000 to over $5,000, enhancing revenue diversity and sustainability.
- Manufacturing Capacity Expansion Plans: The company anticipates producing one GenesisX robot every two months in 2026 and ramping MAGiC catheter production from 100 to 500 units per month in partnership with Osypka, aiming to meet growing market demand and overcome manufacturing bottlenecks.
See More
Stereotaxis Q4 Earnings Report Analysis
- Earnings Performance: Stereotaxis reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.01, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Growth: The company's Q4 revenue reached $8.64 million, reflecting a 36.3% year-over-year increase, although it fell short of market expectations by $0.6 million, suggesting room for improvement in market demand.
- Market Reaction Analysis: Despite missing revenue expectations, the earnings beat may positively influence investor sentiment, potentially increasing stock price volatility in the short term, reflecting market interest in the company's future potential.
- Historical Financial Data Comparison: Analyzing historical financial data, Stereotaxis shows a revenue growth trend that highlights its competitive position in the medical device sector, with prospects for achieving higher revenue levels through ongoing innovation and market expansion.
See More
Stereotaxis to Announce Q4 Earnings on March 9th
- Earnings Announcement Date: Stereotaxis is set to release its Q4 earnings on March 9th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Estimate Analysis: The consensus EPS estimate stands at -$0.07, reflecting a 22.2% year-over-year increase, indicating the company's efforts to improve profitability despite still being in the negative.
- Revenue Growth Expectations: The consensus revenue estimate is $9.24 million, representing a 45.7% year-over-year increase, showcasing strong sales momentum amid rising market demand.
- Historical Performance Review: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, highlighting challenges in meeting profitability expectations.
See More
Stereotaxis Receives FDA Approval for MAGiC Magnetic Ablation Catheter
- FDA Approval: Stereotaxis announced it has received FDA approval for its MAGiC Magnetic Interventional Ablation Catheter, marking a significant advancement in surgical robotics and is expected to drive market demand for cardiac ablation therapies.
- Technological Innovation: The MAGiC catheter utilizes robotic navigation and computer-controlled magnetic fields to offer levels of precision and stability often unattainable with traditional catheters, aiming to improve treatment outcomes for complex patient populations, particularly those with arrhythmias.
- Market Expansion: This catheter is specifically designed for patients with anatomical abnormalities or prior surgical interventions that limit access via conventional manual catheter navigation, which is expected to significantly enhance the accessibility of minimally invasive cardiac ablation therapies to underserved patient populations.
- Strategic Implications: The FDA approval not only enhances Stereotaxis's competitiveness in the cardiac treatment space but also has the potential to generate new revenue streams, further solidifying its leadership position in the surgical robotics market.
See More
Stereotaxis Receives FDA Approval for MAGiC Catheter, Advancing Cardiac Treatment Technology
- FDA Approval Milestone: Stereotaxis's receipt of FDA approval for the MAGiC catheter marks a significant advancement in cardiac electrophysiology, enabling complex arrhythmia patients to benefit from robotic magnetic navigation technology, thereby enhancing the company's competitiveness in the medical device market.
- Technological Innovation: The MAGiC catheter is navigated by highly precise computer-controlled magnetic fields, offering maneuverability and stability levels often unattainable with traditional catheters, which is expected to significantly improve the safety and efficacy of cardiac ablation procedures.
- Market Potential: Designed for complex patient populations that are difficult to treat with conventional methods, the catheter is anticipated to expand Stereotaxis's market share in cardiac care, addressing the growing medical demand.
- Clinical Impact: The launch of the MAGiC catheter will not only promote the application of robotic technology in electrophysiology but also provide physicians with safer and more effective treatment options, further solidifying Stereotaxis's leadership in innovative medical technology.
See More
Stereotaxis Reports 36% Revenue Growth in Q4
- Significant Revenue Growth: Stereotaxis Inc (STXS) reported fourth-quarter revenue of $8.6 million, a 36% increase from $6.3 million in the prior year, reflecting strong performance in system and catheter sales, which enhances the company's competitive position in the medical device market.
- Product Portfolio Expansion: The company plans to launch MAGiC with Pulse Field Ablation in Europe by year-end, aiming to boost revenue potential through new product marketing, although the commercial contribution from new products remained modest in 2025.
- Operational Cost Challenges: Operating expenses for Q4 reached $10 million, including $3 million in non-cash charges, and while adjusted operating expenses were $7 million, high operational costs continue to pressure financial results, impacting the company's profitability.
- Cash Flow Position: As of the end of 2025, Stereotaxis had cash and cash equivalents of $13.4 million, facing a negative free cash flow of $13.8 million; however, the company's debt-free status provides a safeguard for future growth.
See More
Stereotaxis Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Q4 2025 revenue reached $8.6 million, a 36% increase year-over-year, reflecting substantial progress in catheter sales, with annual revenue projected to exceed $40 million in 2026, indicating strong market demand and growth potential.
- Technological Advancements and Regulatory Milestones: The company achieved regulatory approvals for the GenesisX robot and MAGiC catheters in the U.S. and Europe, underscoring its leadership in minimally invasive surgery technology, which is expected to drive future sales and market share growth.
- Commercial Model Transformation: Stereotaxis is shifting from large capital sales to a model based on sales, leases, and placements funded by disposable commitments, increasing revenue per procedure from $1,000 to over $5,000, enhancing revenue diversity and sustainability.
- Manufacturing Capacity Expansion Plans: The company anticipates producing one GenesisX robot every two months in 2026 and ramping MAGiC catheter production from 100 to 500 units per month in partnership with Osypka, aiming to meet growing market demand and overcome manufacturing bottlenecks.
See More
Stereotaxis Q4 Earnings Report Analysis
- Earnings Performance: Stereotaxis reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.01, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Growth: The company's Q4 revenue reached $8.64 million, reflecting a 36.3% year-over-year increase, although it fell short of market expectations by $0.6 million, suggesting room for improvement in market demand.
- Market Reaction Analysis: Despite missing revenue expectations, the earnings beat may positively influence investor sentiment, potentially increasing stock price volatility in the short term, reflecting market interest in the company's future potential.
- Historical Financial Data Comparison: Analyzing historical financial data, Stereotaxis shows a revenue growth trend that highlights its competitive position in the medical device sector, with prospects for achieving higher revenue levels through ongoing innovation and market expansion.
See More
Stereotaxis to Announce Q4 Earnings on March 9th
- Earnings Announcement Date: Stereotaxis is set to release its Q4 earnings on March 9th after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Estimate Analysis: The consensus EPS estimate stands at -$0.07, reflecting a 22.2% year-over-year increase, indicating the company's efforts to improve profitability despite still being in the negative.
- Revenue Growth Expectations: The consensus revenue estimate is $9.24 million, representing a 45.7% year-over-year increase, showcasing strong sales momentum amid rising market demand.
- Historical Performance Review: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, highlighting challenges in meeting profitability expectations.
See More
Stereotaxis Receives FDA Approval for MAGiC Magnetic Ablation Catheter
- FDA Approval: Stereotaxis announced it has received FDA approval for its MAGiC Magnetic Interventional Ablation Catheter, marking a significant advancement in surgical robotics and is expected to drive market demand for cardiac ablation therapies.
- Technological Innovation: The MAGiC catheter utilizes robotic navigation and computer-controlled magnetic fields to offer levels of precision and stability often unattainable with traditional catheters, aiming to improve treatment outcomes for complex patient populations, particularly those with arrhythmias.
- Market Expansion: This catheter is specifically designed for patients with anatomical abnormalities or prior surgical interventions that limit access via conventional manual catheter navigation, which is expected to significantly enhance the accessibility of minimally invasive cardiac ablation therapies to underserved patient populations.
- Strategic Implications: The FDA approval not only enhances Stereotaxis's competitiveness in the cardiac treatment space but also has the potential to generate new revenue streams, further solidifying its leadership position in the surgical robotics market.
See More
Stereotaxis Receives FDA Approval for MAGiC Catheter, Advancing Cardiac Treatment Technology
- FDA Approval Milestone: Stereotaxis's receipt of FDA approval for the MAGiC catheter marks a significant advancement in cardiac electrophysiology, enabling complex arrhythmia patients to benefit from robotic magnetic navigation technology, thereby enhancing the company's competitiveness in the medical device market.
- Technological Innovation: The MAGiC catheter is navigated by highly precise computer-controlled magnetic fields, offering maneuverability and stability levels often unattainable with traditional catheters, which is expected to significantly improve the safety and efficacy of cardiac ablation procedures.
- Market Potential: Designed for complex patient populations that are difficult to treat with conventional methods, the catheter is anticipated to expand Stereotaxis's market share in cardiac care, addressing the growing medical demand.
- Clinical Impact: The launch of the MAGiC catheter will not only promote the application of robotic technology in electrophysiology but also provide physicians with safer and more effective treatment options, further solidifying Stereotaxis's leadership in innovative medical technology.
See More
